{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T21:24:39Z","timestamp":1793309079200,"version":"4.5.0"},"reference-count":35,"publisher":"American Diabetes Association","issue":"8","license":[{"start":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T00:00:00Z","timestamp":1719014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"funder":[{"name":"Novo Nordisk A\/S"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>To evaluate the cardiovascular effects of semaglutide by baseline glycated hemoglobin (HbA1c) and change in HbA1c in a prespecified analysis of Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>In SELECT, people with overweight or obesity and atherosclerotic cardiovascular disease without diabetes were randomized to weekly semaglutide 2.4 mg or placebo. The primary end point of first major adverse cardiovascular event (MACE) (cardiovascular mortality, nonfatal myocardial infarction, or stroke) was reduced by 20% with semaglutide versus placebo. Analysis of outcomes included first MACE, its individual components, expanded MACE (cardiovascular mortality, nonfatal myocardial infarction, or stroke; coronary revascularization; or hospitalization for unstable angina), a heart failure composite (heart failure hospitalization or urgent medical visit or cardiovascular mortality), coronary revascularization, and all-cause mortality by baseline HbA1c subgroup and categories of HbA1c change (&amp;lt;\u22120.3, \u22120.3 to 0.3, and &amp;gt;0.3 percentage points) from baseline to 20 weeks using the intention-to-treat principle with Cox proportional hazards.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Among 17,604 participants (mean age 61.6 years, 72.3% male), baseline HbA1c was &amp;lt;5.7% for 33.5%, 5.7% to &amp;lt;6.0% for 34.6%, and 6.0% to &amp;lt;6.5% for 31.9%. Cardiovascular risk reduction with semaglutide versus placebo was not shown to be different across baseline HbA1c groups and was consistent with that of the overall study for all end points, except all-cause mortality. Cardiovascular outcomes were also consistent across subgroups of HbA1c change.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>In people with overweight or obesity and established atherosclerotic cardiovascular disease but not diabetes, semaglutide reduced cardiovascular events irrespective of baseline HbA1c or change in HbA1c. Thus, semaglutide is expected to confer cardiovascular benefits in people with established atherosclerotic cardiovascular disease who are normoglycemic at baseline and\/or in those without HbA1c improvements.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title\/>\n               <\/jats:sec>","DOI":"10.2337\/dc24-0764","type":"journal-article","created":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T12:00:44Z","timestamp":1719057644000},"page":"1360-1369","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":64,"title":["Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT"],"prefix":"10.2337","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7006-7401","authenticated-orcid":false,"given":"Ildiko","family":"Lingvay","sequence":"first","affiliation":[{"name":"1Department of Internal Medicine\/Endocrinology and Peter O\u2019Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Deanfield","sequence":"additional","affiliation":[{"name":"2Institute of Cardiovascular Science, University College London, London, U.K"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E.","family":"Kahn","sequence":"additional","affiliation":[{"name":"3VA Puget Sound Health Care System and University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter E.","family":"Weeke","sequence":"additional","affiliation":[{"name":"4Novo Nordisk A\/S, S\u00f8borg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Toplak","sequence":"additional","affiliation":[{"name":"5Division of Endocrinology and Diabetology, Department of Medicine, Medical University of Graz, Graz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin M.","family":"Scirica","sequence":"additional","affiliation":[{"name":"6TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5430-4697","authenticated-orcid":false,"given":"Lars","family":"Ryd\u00e9n","sequence":"additional","affiliation":[{"name":"7Department of Medicine K2, Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen","family":"Rathor","sequence":"additional","affiliation":[{"name":"4Novo Nordisk A\/S, S\u00f8borg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Plutzky","sequence":"additional","affiliation":[{"name":"8Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristobal","family":"Morales","sequence":"additional","affiliation":[{"name":"9Vithas Hospital, Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Michael","family":"Lincoff","sequence":"additional","affiliation":[{"name":"10Department of Cardiovascular Medicine, Cleveland Clinic, and Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2484-8068","authenticated-orcid":false,"given":"Michael","family":"Lehrke","sequence":"additional","affiliation":[{"name":"11University of Aachen, Aachen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole Kleist","family":"Jeppesen","sequence":"additional","affiliation":[{"name":"4Novo Nordisk A\/S, S\u00f8borg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz","family":"Gajos","sequence":"additional","affiliation":[{"name":"12Department of Coronary Artery Disease and Heart Failure, Jagiellonian University Medical College, Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8345-3288","authenticated-orcid":false,"given":"Helen M.","family":"Colhoun","sequence":"additional","affiliation":[{"name":"13Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, U.K"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1580-8040","authenticated-orcid":false,"given":"Bertrand","family":"Cariou","sequence":"additional","affiliation":[{"name":"14L\u2019institut du thorax, INSERM, CNRS, CHU Nantes, Nantes Universit\u00e9, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8374-2277","authenticated-orcid":false,"given":"Donna","family":"Ryan","sequence":"additional","affiliation":[{"name":"15Pennington Biomedical Research Center, Baton Rouge, LA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"SELECT Trial Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2024,6,22]]},"reference":[{"key":"2024080521453881300_B1","doi-asserted-by":"crossref","first-page":"413","DOI":"10.7326\/0003-4819-141-6-200409210-00006","article-title":"Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk","volume":"141","author":"Khaw","year":"2004","journal-title":"Ann Intern Med"},{"key":"2024080521453881300_B2","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.jacc.2009.10.060","article-title":"Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence","volume":"55","author":"Ford","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2024080521453881300_B3","doi-asserted-by":"crossref","first-page":"e015949","DOI":"10.1136\/bmjopen-2017-015949","article-title":"Glycated haemoglobin A1c as a risk factor of cardiovascular outcomes and all-cause mortality in diabetic and non-diabetic populations: a systematic review and meta-analysis","volume":"7","author":"Cavero-Redondo","year":"2017","journal-title":"BMJ Open"},{"key":"2024080521453881300_B4","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur Heart J"},{"key":"2024080521453881300_B5","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa1010949","article-title":"Pioglitazone for diabetes prevention in impaired glucose tolerance","volume":"364","author":"DeFronzo","year":"2011","journal-title":"N Engl J Med"},{"key":"2024080521453881300_B6","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1464-5491.2012.03750.x","article-title":"Long-term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study","volume":"30","author":"Orchard","year":"2013","journal-title":"Diabet Med"},{"key":"2024080521453881300_B7","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.2337\/diabetes.54.4.1150","article-title":"prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program","volume":"54","author":"Knowler WC, Hamman RF, Edelstein SL, et al","year":"2005","journal-title":"Diabetes"},{"key":"2024080521453881300_B8","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N Engl J Med"},{"key":"2024080521453881300_B9","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2337\/diacare.27.1.155","article-title":"XENical in the prevention of Diabetes in Obese Subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients","volume":"27","author":"Torgerson","year":"2004","journal-title":"Diabetes Care"},{"key":"2024080521453881300_B10","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12933-019-0916-z","article-title":"Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis","volume":"18","author":"Fei","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"2024080521453881300_B11","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2024080521453881300_B12","doi-asserted-by":"crossref","first-page":"356","DOI":"10.2337\/dc17-1096","article-title":"How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial","volume":"41","author":"Inzucchi","year":"2018","journal-title":"Diabetes Care"},{"key":"2024080521453881300_B13","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1002\/ehf2.13615","article-title":"Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial","volume":"8","author":"Fitchett","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2024080521453881300_B14","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.2337\/dc19-2251","article-title":"Cardiovascular risk reduction with liraglutide: an exploratory mediation analysis of the LEADER trial","volume":"43","author":"Buse","year":"2020","journal-title":"Diabetes Care"},{"key":"2024080521453881300_B15","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s12933-021-01386-4","article-title":"Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND","volume":"20","author":"Konig","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"2024080521453881300_B16","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S2213-8587(17)30033-5","article-title":"Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes","volume":"5","author":"Standl","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2024080521453881300_B17","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2024080521453881300_B18","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ahj.2020.07.008","article-title":"Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design","volume":"229","author":"Ryan","year":"2020","journal-title":"Am Heart J"},{"key":"2024080521453881300_B19","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/oby.23621","article-title":"Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics","volume":"31","author":"Lingvay","year":"2023","journal-title":"Obesity (Silver Spring)"},{"key":"2024080521453881300_B20","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.2337\/dc24-S002","article-title":"2. Diagnosis and classification of diabetes: Standards of Care in Diabetes\u20142024","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","journal-title":"Diabetes Care"},{"key":"2024080521453881300_B21","author":"International Diabetes Federation","year":"2021"},{"key":"2024080521453881300_B22","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2024080521453881300_B23","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"2024080521453881300_B24","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"2024080521453881300_B25","first-page":"1094","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"374","author":"Zinman","year":"2016","journal-title":"N Engl J Med"},{"key":"2024080521453881300_B26","first-page":"1350","volume-title":"Diabetes Care","author":"Kahn","year":"2024"},{"key":"2024080521453881300_B27","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/jama.290.4.486","article-title":"Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial","volume":"290","author":"Chiasson","year":"2003","journal-title":"JAMA"},{"key":"2024080521453881300_B28","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S2213-8587(17)30309-1","article-title":"Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial","volume":"5","author":"Holman","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2024080521453881300_B29","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1161\/CIRCULATIONAHA.121.056756","article-title":"Effects of long-term metformin and lifestyle interventions on cardiovascular events in the Diabetes Prevention Program and its outcome study","volume":"145","author":"Goldberg","year":"2022","journal-title":"Circulation"},{"key":"2024080521453881300_B30","doi-asserted-by":"crossref","first-page":"e5656","DOI":"10.1371\/journal.pone.0005656","article-title":"Ten-year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study--secondary analysis of the randomized trial","volume":"4","author":"Uusitupa","year":"2009","journal-title":"PLoS One"},{"key":"2024080521453881300_B31","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/S0140-6736(08)60766-7","article-title":"The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study","volume":"371","author":"Li","year":"2008","journal-title":"Lancet"},{"key":"2024080521453881300_B32","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.2337\/dc14-2498","article-title":"Cardiovascular and all-cause mortality over a 23-year period among Chinese with newly diagnosed diabetes in the Da Qing IGT and Diabetes Study","volume":"38","author":"An","year":"2015","journal-title":"Diabetes Care"},{"key":"2024080521453881300_B33","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S2213-8587(19)30093-2","article-title":"Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study","volume":"7","author":"Gong","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2024080521453881300_B34","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cmet.2016.06.009","article-title":"The cardiovascular biology of glucagon-like peptide-1","volume":"24","author":"Drucker","year":"2016","journal-title":"Cell Metab"},{"key":"2024080521453881300_B35","doi-asserted-by":"crossref","first-page":"726","DOI":"10.2337\/dc19-2165","article-title":"Screening for glucose perturbations and risk factor management in dysglycemic patients with coronary artery disease\u2014a persistent challenge in need of substantial improvement: a report from ESC EORP EUROASPIRE V","volume":"43","author":"Ferrannini","year":"2020","journal-title":"Diabetes Care"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/47\/8\/1360\/777932\/dc240764.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/47\/8\/1360\/777932\/dc240764.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T21:46:16Z","timestamp":1722894376000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/47\/8\/1360\/156810\/Semaglutide-and-Cardiovascular-Outcomes-by"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,22]]},"references-count":35,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,6,22]]},"published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc24-0764","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,22]]}}}